Search academic texts

Information × Registration Number 0214U001446, 0112U004849 , R & D reports Title To optimize the treatment of relapsed and refractory malignant lymphoma and multiple myeloma patients (multicenter study). popup.stage_title Head Kryachok Iryna, Registration Date 18-02-2014 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 Object of study - patients with refractory and relapse of Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma. Purpose - to develop and optimize differential treatment programs for patients with refractory and relapsed of Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma with the latest schemes of chemotherapy and stem cell transplantation based on the complex of clinical - hematological, immunophenotypic and molecular - genetic criteria. Research Methods and apparatus: morphological, immunohistochemical, clinical and statistical. The treatment of 129 patients with refractory and relapsed forms of non-Hodgkins lymphoma, Hodgkin's lymphoma. The highest efficiency was in group of patients with recurrent and primary refractory Hodgkin's lymphoma and NHL forms who were treated with II line schemes : DHAP, GVP. Overall response to therapy significantly higher in patients with Hodgkin's lymphoma and - 73.07 %, in patients with NHL - 48%. Direct effectiveness of treatment schemes using cisplatin has greater efficiency (74.8 and 63.3 % in patients with HL and NHL, respectively) than treatment regimens with gemcitabine ( 44.8 and 36.3 %, respectively). The level of expression of ki-67 protein in more than 45 % of the tumor cells has independent predictive value for disease-free performance, and overall survival. The five-year overall survival in patients with levels of antigen expression ki-67 tumor cells in <45 % is significantly higher (83.0 % ) compared with patients with expression level > 45 % (46,9%), p <0,05. It has been established that direct treatment efficiency is higher in patients with absence of expression of LH EBV compared with the group of subjects with the expression of the marker (53.6 % and 22.4 %, respectively ) (p <0,05). Molecular - genetic factors prognosis of the disease relates genotype Val / Val gene GSTP1. Analyzed the treatment of 105 patients with multiple myeloma treated with thalidomide - based combination chemotherapy. Direct treatment efficiency was 69.1%, a complete response was observed in 27.6 % of patients at 41.4% - a partial response. We obtained previously positive treatment results of patients with refractory and relapsed non-Hodgkin's lymphoma and multiple myeloma indicate its prospects and the need for continued research. Scope - oncology. Product Description popup.authors Мартинчик А.В. Новосад О.І. Титоренко І.Б. Яценко Л.Д. popup.nrat_date 2020-04-02 Close